指南与共识肿瘤 PET/CT放射性药物与辐射防护

SNMMI/EANM儿童肿瘤18F-FDG PET/CT操作标准与实践指南1.0版

SNMMI Procedure Standard/EANM Practice Guideline on Pediatric 18F-FDG PET/CT for Oncology 1.0.
指南 / 共识 · J Nucl Med · 2021-01-01

该指南由SNMMI与EANM以共识流程制定,面向儿童肿瘤患者,规范18F-FDG PET/CT的推荐、执行与解读。文中推荐基于专家意见,证据水平不高,需结合核医学良好实践及当地法规使用。

要点

  • 适用于儿童肿瘤患者的18F-FDG PET/CT推荐、执行与解读。
  • 推荐代表领域专家意见,并非所有推荐均有高证据水平。
  • 指南为教育工具,不替代临床判断与法规要求。

核心结论

  • 指南为儿童肿瘤18F-FDG PET/CT的推荐、执行与解读提供专家共识框架,非强制规则。

研究设计与样本

  • SNMMI与EANM经全面共识流程制定,每5年或更早审查修订。

主要发现

  • 18F-FDG是PET显像最常用放射性示踪剂,PET与CT已广泛用于肿瘤学。

关键数值与推荐

  • 文中推荐代表该领域有经验专家的意见,并非均有高证据水平。

临床怎么用

  • 临床决策应结合患者具体情况、可用资源及知识技术进展,可合理偏离指南。

局限性

  • 推荐证据水平不高,需进一步研究以获得儿童肿瘤应用的循证推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PREAMBLEThe Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and professional organization founded in 1954 to promote the science, technology, and practical application of nuclear medicine. The European Association of Nuclear Medicine (EANM) is a professional nonprofit medical association founded in 1985 to facilitate communication worldwide among individuals pursuing clinical and academic excellence in nuclear medicine. SNMMI and EANM members are physicians, technologists, and scientists specializing in the research and practice of nuclear medicine.The SNMMI and EANM will periodically put forth new standards/guidelines for nuclear medicine practice to help advance the science of nuclear medicine and improve service to patients. Existing standards/guidelines will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated. Each standard/guideline, representing a policy statement by the SNMMI/EANM, has undergone a thorough consensus process, entailing extensive review. The SNMMI and EANM recognize that the safe and effective use of diagnostic nuclear medicine imaging requires particular training and skills, as described in each document. These standards/guidelines are educational tools designed to assist practitioners in providing appropriate and effective nuclear medicine care for patients. These guidelines are consensus documents, and are not inflexible rules or requirements of practice. They are not intended, nor should they be used, to establish a legal standard of care. For these reasons and those set forth below, the SNMMI and the EANM cautions against the use of these standards/guidelines in litigation in which the clinical decisions of a practitioner are called into question.The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by medical professionals taking into account the unique circumstances of each case. Thus, there is no implication that action differing from what is laid out in the standards/guidelines, standing alone, is below standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in the standards/guidelines when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology subsequent to publication of the standards/guidelines.The practice of medicine involves not only the science, but also the art of dealing with the prevention, diagnosis, alleviation, and treatment of disease. The variety and complexity of human conditions make it impossible for general guidelines to consistently allow for an accurate diagnosis to be reached or a particular treatment response to be predicted. Therefore, it should be recognized that adherence to these standards/guidelines will not ensure a successful outcome. All that should be expected is that the practitioner follows a reasonable course of action, based on their level of training, the current knowledge, the available resources, and the needs/context of the particular patient being treated.PET and computerized tomography (CT) have been widely used in oncology. 18F-FDG is the most common radiotracer used for PET imaging. The purpose of this document is to provide imaging specialists and clinicians guidelines for recommending, performing, and interpreting 18F-FDG PET/CT in pediatric patients in oncology. There is not a high level of evidence for all recommendations suggested in this paper. These recommendations represent the expert opinions of experienced leaders in this field. Further studies are needed to have evidence-based recommendations for the application of 18F-FDG PET/CT in pediatric oncology. These recommendations should be viewed in the context of good practice of nuclear medicine and are not intended to be a substitute for national and international legal or regulatory provisions.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Vali R, Alessio A, Balza R, et al. SNMMI Procedure Standard/EANM Practice Guideline on Pediatric 18F-FDG PET/CT for Oncology 1.0. J Nucl Med. 2021. PMID: 33334912. doi:10.2967/jnumed.120.254110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。